Tag
This article explores the mechanism by which HBV induces liver fibrosis through pyruvate-dependent ROS production and PPARα inhibition, highlighting novel therapeutic targets for chronic hepatitis B management.
A study reveals CD16+ γδ T cells as key mediators of antibody-dependent cellular cytotoxicity in HBV infection, correlating with reduced viral replication and offering new therapeutic targets.
This review synthesizes the Phase 1 trial findings of ALG-000184, a novel capsid assembly modulator, demonstrating significant multi-log reductions in HBV DNA and RNA with a favorable safety profile in chronic HBV patients.
A large Asian cohort study shows serum HBsAg <100 IU/mL reliably identifies inactive chronic hepatitis B patients whose annual HCC risk is <0.2%, potentially allowing de‑escalation of surveillance and informing partial HBV cure defini
This article explores how alcohol consumption worsens HBV-induced hepatocellular carcinoma by promoting ER stress and lipid metabolic disturbances, highlighting potential therapeutic targets like LPLA2 and BMP.
SCG101, an HBV-specific T-cell receptor T-cell therapy, demonstrates significant antiviral and antitumour efficacy with a manageable safety profile in patients with advanced HBV-related hepatocellular carcinoma refractory to prior treatment
